AU2002351181B2 - Methods and compositions for treating lesions of the respiratory epithelium - Google Patents

Methods and compositions for treating lesions of the respiratory epithelium Download PDF

Info

Publication number
AU2002351181B2
AU2002351181B2 AU2002351181A AU2002351181A AU2002351181B2 AU 2002351181 B2 AU2002351181 B2 AU 2002351181B2 AU 2002351181 A AU2002351181 A AU 2002351181A AU 2002351181 A AU2002351181 A AU 2002351181A AU 2002351181 B2 AU2002351181 B2 AU 2002351181B2
Authority
AU
Australia
Prior art keywords
seq
composition
trefoil
itf
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002351181A
Other languages
English (en)
Other versions
AU2002351181A1 (en
Inventor
Daniel K. Podolsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2002351181A1 publication Critical patent/AU2002351181A1/en
Application granted granted Critical
Publication of AU2002351181B2 publication Critical patent/AU2002351181B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002351181A 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium Ceased AU2002351181B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33383601P 2001-11-28 2001-11-28
US60/333,836 2001-11-28
PCT/US2002/038258 WO2003045332A2 (en) 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium

Publications (2)

Publication Number Publication Date
AU2002351181A1 AU2002351181A1 (en) 2003-06-10
AU2002351181B2 true AU2002351181B2 (en) 2008-08-07

Family

ID=23304463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002351181A Ceased AU2002351181B2 (en) 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium

Country Status (8)

Country Link
US (2) US20030114384A1 (https=)
EP (1) EP1461076A4 (https=)
JP (1) JP2005532988A (https=)
CN (1) CN1617739A (https=)
AU (1) AU2002351181B2 (https=)
CA (1) CA2468344A1 (https=)
MX (1) MXPA04005053A (https=)
WO (1) WO2003045332A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525018B1 (en) 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
US6610043B1 (en) 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
US7654998B1 (en) 1999-08-23 2010-02-02 Aeris Therapeutics, Inc. Tissue volume reduction
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof
US20060189526A1 (en) * 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
WO2003030824A2 (en) * 2001-10-05 2003-04-17 The General Hospital Corporation Methods and compositions for treating dermal lesions
WO2003078579A2 (en) * 2002-03-11 2003-09-25 Aeris Therapeutics, Inc. Compositions and methods for treating emphysema
AU2003224773B2 (en) * 2002-03-26 2010-08-26 The General Hospital Corporation Combination therapy using trefoil peptides
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
WO2004064860A1 (en) * 2003-01-17 2004-08-05 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
AU2005231479C1 (en) * 2004-04-05 2012-03-15 Sunovion Pharmaceuticals Inc. (R,R)-formoterol in combination with other pharmacological agents
US8075771B2 (en) * 2005-02-17 2011-12-13 E. I. Du Pont De Nemours And Company Apparatus for magnetic field gradient enhanced centrifugation
US20100144646A1 (en) * 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
HRP20141047T1 (hr) * 2008-08-01 2015-01-02 Eye Therapies Llc Pripravci za sužavanje krvnih žila i metode njihove uporabe
CN103096917A (zh) * 2010-06-04 2013-05-08 三叶草私人有限公司 用于治疗慢性肺病的三叶因子（tff）
CN105582526B (zh) * 2016-02-25 2020-07-17 山东睿鹰制药集团有限公司 三叶因子2在制备治疗及预防肺/支气管急性炎症疾病药物方面的应用
JP7579880B2 (ja) * 2020-03-30 2024-11-08 山東睿鷹制薬集團有限公司 新型コロナウイルス感染の治療におけるＴＦＦ２タンパク質とＩＦＮ－κタンパク質の併用の応用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014837A1 (en) * 1991-02-14 1992-09-03 The General Hospital Corporation Intestinal trefoil proteins
US5783416A (en) * 1993-01-21 1998-07-21 Novo Nordisk A/S Human spasmolytic polypeptide in glycosylated form
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4370317A (en) * 1980-09-10 1983-01-25 Novo Industri A/S Pancreatic spasmolytic polypeptide
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
WO1999010377A1 (en) * 1997-08-25 1999-03-04 The General Hospital Corporation Receptor for intestinal trefoil factor
BR9913152A (pt) * 1998-08-26 2001-05-15 Smithkline Beecham Corp Terapias para tratamento de doenças pulmonares
US6372439B2 (en) * 1998-10-01 2002-04-16 James R. Goldenring Screen for gastric adenocarcinoma
CA2391594A1 (en) * 1999-12-23 2001-06-28 Human Genome Sciences, Inc. Trefoil domain-containing polynucleotides, polypeptides, and antibodies
EP1341817A2 (en) * 2000-12-08 2003-09-10 Novo Nordisk A/S Tff peptides
MXPA03009772A (es) * 2001-04-24 2004-02-23 Gen Hospital Corp Metodos y composiciones para tratar lesiones orales y del esofago.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014837A1 (en) * 1991-02-14 1992-09-03 The General Hospital Corporation Intestinal trefoil proteins
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US5783416A (en) * 1993-01-21 1998-07-21 Novo Nordisk A/S Human spasmolytic polypeptide in glycosylated form

Also Published As

Publication number Publication date
EP1461076A4 (en) 2005-03-09
CA2468344A1 (en) 2003-06-05
EP1461076A2 (en) 2004-09-29
US20080167230A1 (en) 2008-07-10
CN1617739A (zh) 2005-05-18
US20030114384A1 (en) 2003-06-19
MXPA04005053A (es) 2004-09-10
WO2003045332A3 (en) 2003-07-24
AU2002351181A1 (en) 2003-06-10
WO2003045332A2 (en) 2003-06-05
JP2005532988A (ja) 2005-11-04

Similar Documents

Publication Publication Date Title
US20080167230A1 (en) Methods and compositions for treating or preventing lesions of the respiratory epithelium
US20090227511A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
US11975005B2 (en) Treatment of respiratory diseases
ES2780127T3 (es) Formulación superfina de formoterol
CN102325532B (zh) 用于减轻肺部炎症的左氧氟沙星吸入剂
ES3028423T3 (en) Norketotifen for use in the treatment of respiratory disorders
BRPI0707634A2 (pt) alfa-1 antitripsina para tratar episàdios de exacerbaÇço de doenÇas pulmonares
WO2009115235A1 (en) Pde inhibitors for the treatment of pulmonary hypertension
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
US20220339099A1 (en) Compositions of interleukin-1 receptor antagonist
US12440488B2 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
US20060134009A1 (en) Low dose corticosteroid powders for inhalation
Kearns et al. 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)
Businco et al. Efficacy of Mucoregulatory Therapies Administered by Micronized Vaporization Compared to Nasal Spray in the Treatment of Upper Airway Respiratory Inflammation
WO2024077042A2 (en) Il-1 receptor antagonist treatment for neutrophilic lung disease
WO2025210089A1 (en) A combination of vasoactive intestinal peptide (vip) receptor agonist and a mucolytic agent against inflammatory diseases of the respiratory tract
WO2021211006A1 (en) Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
Ito et al. 90 Inhibitory effects of RV1088, a novel narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis
Ito et al. 89 Superior effects of RV568, a narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis
Keller et al. 91 Medical rationale for nebulisation of a novel high-concentration (100mg/mL) aqueous azithromycin inhalation solution
Janson et al. 4. ACUTE ASTHMA AND COPD EXACERBATIONS
Sierra Inhalation therapy in horses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired